BR112017014229A2 - conjugado, composição, e, método para tratamento de um distúrbio. - Google Patents

conjugado, composição, e, método para tratamento de um distúrbio.

Info

Publication number
BR112017014229A2
BR112017014229A2 BR112017014229-5A BR112017014229A BR112017014229A2 BR 112017014229 A2 BR112017014229 A2 BR 112017014229A2 BR 112017014229 A BR112017014229 A BR 112017014229A BR 112017014229 A2 BR112017014229 A2 BR 112017014229A2
Authority
BR
Brazil
Prior art keywords
conjugate
disorder
treating
composition
conjugates
Prior art date
Application number
BR112017014229-5A
Other languages
English (en)
Inventor
E. Fehr Pereira Lopes José
Original Assignee
Nanocare Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanocare Technologies, Inc. filed Critical Nanocare Technologies, Inc.
Publication of BR112017014229A2 publication Critical patent/BR112017014229A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Abstract

a descrição descreve conjugados de jasmonato e conjugados de jasmonato nanocarreado e/ou microcarreado e composições farmacêuticas dos mesmos, bem como uso dos mesmos para o tratamento ou prevenção de distúrbios relacionados a angiogênese ou a nf-¿¿. também são descritos métodos para a produção dos conjugados.
BR112017014229-5A 2014-12-31 2015-12-31 conjugado, composição, e, método para tratamento de um distúrbio. BR112017014229A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098704P 2014-12-31 2014-12-31
US62/098704 2014-12-31
PCT/US2015/068244 WO2016109779A1 (en) 2014-12-31 2015-12-31 Jasmonate derivatives and compositions thereof

Publications (1)

Publication Number Publication Date
BR112017014229A2 true BR112017014229A2 (pt) 2018-03-06

Family

ID=56285070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014229-5A BR112017014229A2 (pt) 2014-12-31 2015-12-31 conjugado, composição, e, método para tratamento de um distúrbio.

Country Status (11)

Country Link
US (2) US10314918B2 (pt)
EP (1) EP3240534A4 (pt)
JP (1) JP2018502855A (pt)
KR (1) KR20170125811A (pt)
AU (1) AU2015373915A1 (pt)
BR (1) BR112017014229A2 (pt)
CA (1) CA2971870A1 (pt)
IL (1) IL253212A (pt)
MX (1) MX2017008655A (pt)
WO (1) WO2016109779A1 (pt)
ZA (1) ZA201705100B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014526519A (ja) 2011-09-16 2014-10-06 ナノケア テクノロジーズ，インコーポレイティド ジャスモネート化合物の組成物および使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2073507T3 (es) 1989-04-12 1995-08-16 Procter & Gamble Composiciones de productos solidos de consumo que contienen complejos con ciclodextrina en forma de pequeñas particulas.
CA2013485C (en) 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
JP3568325B2 (ja) 1996-07-12 2004-09-22 株式会社ノエビア 抗アンドロゲン剤及び養毛剤並びに毛髪用化粧料
JP3596835B2 (ja) 1996-08-13 2004-12-02 株式会社ノエビア 養毛剤
BR9810429A (pt) 1997-06-09 2000-09-19 Procter & Gamble Composições perfumadas e métodos para reprodução de odores do corpo e excesso de umidade
US6790815B1 (en) 1998-07-10 2004-09-14 Procter & Gamble Company Amine reaction compounds comprising one or more active ingredient
CA2274873A1 (en) 1999-07-06 2001-01-06 Satinder Gidda Methods and compositions for modulating flowering
AU2002245629A1 (en) 2001-03-08 2002-09-24 Targesome, Inc. Stabilized therapeutic and imaging agents
US6469061B1 (en) 2001-04-04 2002-10-22 Ramot University Authority For Applied Research And Industrial Development Limited Jasmonate pharmaceutical composition for treatment of cancer
US20030224024A1 (en) * 2002-02-04 2003-12-04 Jean-Luc Leveque Compositions comprising cyclopentane derivatives and their use
US20040209795A1 (en) 2003-04-21 2004-10-21 Vlad Florin Joseph VOC-free microemulsions
US7425651B2 (en) 2003-12-02 2008-09-16 Ramot At Tel-Aviv University Ltd. Jasmonate derivative compounds, pharmaceuticals compounds and methods of use thereof
KR100789343B1 (ko) 2004-09-07 2007-12-28 주식회사 엘지생활건강 화장용 분체, 그의 제조방법 및 이를 함유하는 메이컵화장품 조성물
US20080044364A1 (en) 2004-11-25 2008-02-21 Christophe Carola Flavonoid Complexes
US7258878B2 (en) 2004-12-20 2007-08-21 Kimberly-Clark Worldwide, Inc. Anti-microbial composition and methods of use thereof
ES2265291B1 (es) 2005-07-22 2008-03-01 Universidad De Alcala Nuevos dendrimeros carbosilanos, su preparacion y sus usos.
AU2006322845A1 (en) * 2005-12-07 2007-06-14 Sepal Pharma Ltd. Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
US20090291904A1 (en) * 2005-12-07 2009-11-26 Yoel Kashman Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
WO2007103336A2 (en) 2006-03-06 2007-09-13 The Board Of Trustees Operating Micro-encapsulation of volatile compounds into cyclodextrins
AU2006344479A1 (en) 2006-06-13 2007-12-21 Cargill, Incorporated Large-particle cyclodextrin inclusion complexes and methods of preparing same
BRPI0714046A2 (pt) 2006-07-10 2013-04-24 Univ Ramot mÉtodos de combinaÇço para tratar cÂncer
BRPI0604024A (pt) 2006-09-01 2008-04-22 Beyond Lifescience Pesquisa De alimentos para a prevenção do cáncer e composições farmacêuticas à base do jasmonato
US20100160623A1 (en) 2006-12-27 2010-06-24 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
WO2009019693A2 (en) 2007-08-07 2009-02-12 Sepal Pharma Sa Analgesic effect of jasmonate derivatives
AU2008303129B2 (en) 2007-09-25 2013-08-01 Formulex Pharma Innovations Ltd. Compositions comprising lipophilic active compounds and method for their preparation
GB0721761D0 (en) 2007-11-06 2007-12-19 Plant Bioscience Ltd Compositions and methods for synergistic manipulation of plant and insect defences
WO2009067404A2 (en) 2007-11-19 2009-05-28 New Biology, Inc. Methods for improving flowering characteristics using methyl dihydrojasmonate
US20090197939A1 (en) 2008-02-01 2009-08-06 Mary Kay Inc. Methods of treating skin with aromatic skin-active ingredients
ES2328002B2 (es) 2008-02-29 2010-03-29 Universidad De Alicante Uso combinado de metil-jasmonato y ciclodextrinas para la produccion de resveratrol.
BRPI0804172A2 (pt) 2008-07-15 2010-07-06 Pereira Lopes Jose Emilio Fehr compostos quìmicos formados a partir de nanoencapsulamentos e complexação de elementos
WO2010143180A1 (en) 2009-06-09 2010-12-16 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
CN101818100B (zh) 2010-04-15 2012-06-06 上海应用技术学院 聚氰基丙烯酸丁酯包覆大花茉莉香精胶囊的制备方法
CN103168018B (zh) * 2010-08-27 2015-10-21 尼昂克技术公司 包含poh衍生物的药物组合物
AU2012221877A1 (en) 2011-02-25 2013-09-19 Nanocare Technologies, Inc. Pharmaceutical formulation comprising compounds of the jasmonate family
JP2014526519A (ja) 2011-09-16 2014-10-06 ナノケア テクノロジーズ，インコーポレイティド ジャスモネート化合物の組成物および使用方法
EP2583998B1 (en) 2011-10-21 2018-02-28 Borealis AG Polyethylene composition with high rapid crack propagation resistance and pressure resistance
US9187402B2 (en) * 2012-06-14 2015-11-17 North Carolina Agricultural And Technical State University Aspirin derivatives and uses thereof
CN104540525A (zh) 2012-07-10 2015-04-22 贝瑟克里科有限公司 大麻素修饰的核酸分子

Also Published As

Publication number Publication date
MX2017008655A (es) 2018-04-10
WO2016109779A1 (en) 2016-07-07
IL253212A (en) 2018-04-30
US10314918B2 (en) 2019-06-11
EP3240534A4 (en) 2018-12-19
CA2971870A1 (en) 2016-07-07
EP3240534A1 (en) 2017-11-08
KR20170125811A (ko) 2017-11-15
ZA201705100B (en) 2021-01-27
US20170368186A1 (en) 2017-12-28
AU2015373915A1 (en) 2017-08-10
US20200164074A1 (en) 2020-05-28
JP2018502855A (ja) 2018-02-01

Similar Documents

Publication Publication Date Title
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201691582A1 (ru) Новые фармацевтические препараты
BR112017007902A2 (pt) composições e métodos para o tratamento de distúrbios do sistema nervoso central.
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112017003111A2 (pt) composições e métodos para o tratamento de distúrbios neurológicos
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112017010173A2 (pt) composição para tratamento de tecido
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112015019909A2 (pt) Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692109A1 (ru) Варианты антител к фактору d и их применение
BR112017010177A2 (pt) composição para tratamento de tecido
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112017000714A2 (pt) indols funcionalizados e substituídos como agentes anti-câncer
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
BR112018011633A2 (pt) inibidores de aza-benzimidazol de pad4
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements